{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T17:51:17Z","timestamp":1792950677896,"version":"4.5.0"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,3,24]]},"abstract":"<jats:p>An extensive clinical development program (comprising two phase 2 and five phase 3 trials) has demonstrated the efficacy and safety of ceftazidime-avibactam in the treatment of adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI), and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP). During the phase 3 clinical program, updated population pharmacokinetic (PK) modeling and Monte Carlo simulations using clinical PK data supported modified ceftazidime-avibactam dosage adjustments for patients with moderate or severe renal impairment (comprising a 50% increase in total daily dose compared with the original dosage adjustments) to reduce the risk of subtherapeutic drug exposures in the event of rapidly improving renal function.<\/jats:p>","DOI":"10.1128\/aac.02105-19","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T10:54:10Z","timestamp":1580727250000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":32,"title":["Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam"],"prefix":"10.1128","volume":"64","author":[{"given":"Jianguo","family":"Li","sequence":"first","affiliation":[{"name":"AstraZeneca, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lovern","sequence":"additional","affiliation":[{"name":"Certara Strategic Consulting, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Riccobene","sequence":"additional","affiliation":[{"name":"Allergan plc, Madison, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Carrothers","sequence":"additional","affiliation":[{"name":"Allergan plc, Madison, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Newell","sequence":"additional","affiliation":[{"name":"AstraZeneca, Macclesfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-4816","authenticated-orcid":false,"given":"Shampa","family":"Das","sequence":"additional","affiliation":[{"name":"AstraZeneca, Macclesfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela K.","family":"Talley","sequence":"additional","affiliation":[{"name":"Allergan plc, Madison, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Tawadrous","sequence":"additional","affiliation":[{"name":"Pfizer, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"Pfizer. 2020. Summary of product characteristics: Zavicefta 2 g\/0.5 g powder for concentrate for solution for infusion. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004027\/WC500210234.pdf."},{"key":"e_1_3_3_3_2","unstructured":"Allergan. 2019. AVYCAZ (ceftazidime and avibactam) for injection for intravenous use. https:\/\/www.allergan.com\/assets\/pdf\/avycaz_pi."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.748653"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks523"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw133"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30004-4"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw378"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.010"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30747-8"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.25.2.201"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.055335"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.793"},{"key":"e_1_3_3_15_2","unstructured":"Li J Zhou D Nichols W Das S. 2012. Evaluation of ceftazidime-avibactam (CAZ-AVI) dose regimens for phase III study in patients with different renal function abstr A-635. Abstr 52nd Intersci Conf Antimicrob Agents Chemother San Francisco CA."},{"key":"e_1_3_3_16_2","unstructured":"Li J Knebel W Riggs M Zhou D Nichols W Das S. 2012. Population pharmacokinetic modelling of ceftazidime (CAZ) and avibactam (AVI) in healthy volunteers and patients with complicated intra-abdominal infection (cIAI) abstr A-634. Abstr 52nd Intersci Conf Antimicrob Agents Chemother San Francisco CA."},{"key":"e_1_3_3_17_2","unstructured":"Li J Zhou D Das S Lovern MR Wada R Bellanti F Riccobene TA Carrothers TJ Al-Huniti N. 2015. PK\/PD target attainment analyses and assessment of dose adjustments for renal insufficiency for ceftazidime-avibactam (CAZ-AVI) in patients with complicated intra-abdominal infection (cIAI) complicated urinary tract infection (cUTI) or nosocomial pneumonia (NP) abstr 2459. Am Assoc Pharm Sci Annu Meet Exposition Orlando FL."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12585"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01269-15"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00080-14"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02446-17"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02590-17"},{"key":"e_1_3_3_23_2","unstructured":"GlaxoSmithKline. 2007. FORTAZ (ceftazidime for injection). Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/050578s053 050634s020lbl.pdf."},{"key":"e_1_3_3_24_2","unstructured":"GlaxoSmithKline. 2010. Summary of product characteristics: ceftazidime 1 g 2 g 3 g powder for solution for injection or infusion. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Fortum_30\/WC500098366.pdf."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz149"},{"key":"e_1_3_3_26_2","unstructured":"Talley A Riccobene T Critchley I Rekeda L Melnick D. 2018. Outcomes among patients with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia stratified by renal function: subgroup analysis from a phase 3 study of ceftazidime-avibactam abstr SUNDAY 684. ASM Microbe 2018 Atlanta GA."},{"key":"e_1_3_3_27_2","unstructured":"Li J Zhou D Das S Lovern M Green M Chiu J Riccobene T Carrothers T Al-Huniti N. 2015. Population PK modeling for ceftazidime-avibactam (CAZ-AVI) in patients with complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI) abstr 2472. Am Assoc Pharm Sci Annu Meet Exposition Orlando FL."},{"key":"e_1_3_3_28_2","unstructured":"Pfizer Inc. 2015. Data on file. CAZ MS-06 modeling and simulation analysis report."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-017-4780-6"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2023"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2015.02.001"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2184"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy790"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw486"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-016-0143-9"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1840"},{"key":"e_1_3_3_37_2","unstructured":"Pfizer Inc. 2013 Data on file. CAZ-AVI technical report 14 October 2013 (CAZ MS-04)."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02105-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02105-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:35:12Z","timestamp":1645486512000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02105-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,3,24]]}},"alternative-id":["10.1128\/AAC.02105-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02105-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"assertion":[{"value":"2020-03-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02105-19"}}